Abou Alaiwi, S., Xie, W., Nassar, A. H., Dudani, S., Martini, D., Bakouny, Z., . . . Harshman, L. C. (2020). Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma. J Immunother Cancer.
Citación estilo ChicagoAbou Alaiwi, Sarah, et al. "Safety and Efficacy of Restarting Immune Checkpoint Inhibitors After Clinically Significant Immune-related Adverse Events in Metastatic Renal Cell Carcinoma." J Immunother Cancer 2020.
Cita MLAAbou Alaiwi, Sarah, et al. "Safety and Efficacy of Restarting Immune Checkpoint Inhibitors After Clinically Significant Immune-related Adverse Events in Metastatic Renal Cell Carcinoma." J Immunother Cancer 2020.